FindTrial
Sign In

LY3209590

DRUG12 trials

Sponsors

Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 2HealthyType 1 Diabetes MellitusType 2 Diabetes Mellitus

Phase 1

A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes
CompletedNCT02942914
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2016-12-20End: 2017-10-18Updated: 2017-11-07
A Study of LY3209590 in Participants With Type 2 Diabetes
CompletedNCT03367377
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2018-01-03End: 2018-10-03Updated: 2018-12-11
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes
CompletedNCT03603704
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2018-08-17End: 2019-05-27Updated: 2020-11-17
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus
CompletedNCT04276428
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2020-02-28End: 2020-11-28Updated: 2020-12-03
A Study of Two Different Formulations of LY3209590 in Healthy Participants
CompletedNCT04768842
Eli Lilly and CompanyHealthy
Start: 2021-03-03End: 2021-09-03Updated: 2021-09-27
A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus
CompletedNCT04957914
Eli Lilly and CompanyType 2 Diabetes Mellitus
Start: 2021-07-14End: 2022-10-17Updated: 2022-11-16
A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus
CompletedNCT05596747
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2022-11-30End: 2023-10-10Updated: 2024-01-02
A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes
CompletedNCT06169982
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2023-12-07End: 2024-07-18Updated: 2024-09-04
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
CompletedNCT06362265
Eli Lilly and CompanyType 2 Diabetes Mellitus
Start: 2024-10-10End: 2026-01-02Updated: 2026-03-24

Phase 2

A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
CompletedNCT03736785
Eli Lilly and CompanyType 2 Diabetes Mellitus
Start: 2018-11-15End: 2020-02-18Updated: 2021-03-08
A Study of LY3209590 in Participants With Type 1 Diabetes
CompletedNCT04450407
Eli Lilly and CompanyType 1 Diabetes Mellitus
Start: 2020-07-06End: 2021-10-01Updated: 2022-10-27
A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
CompletedNCT04450394
Eli Lilly and CompanyType 2 Diabetes Mellitus
Start: 2020-07-01End: 2021-10-08Updated: 2022-11-02

Related Papers

Pharmacokinetics, Pharmacodynamics, and Safety of Once-Weekly Insulin Efsitora Alfa in Chinese Patients with Type 2 Diabetes: A Phase 1 Open-Label, Randomized, Active-Controlled Trial.
2026-07-09
Pharmacokinetic and Pharmacodynamic Properties of Once-Weekly Insulin Efsitora Alfa in Japanese Patients with Type 2 Diabetes
Diabetes Therapy2025-02-102 citations
Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes.
2024-06-225 citations
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
2023-02-0636 citations
802-P: Safety, Pharmacokinetics, and Pharmacodynamics of Once-Weekly Basal Insulin Fc (BIF) in Japanese Patients with Type 2 Diabetes: A Phase 1 Open-Label, Randomized, Active-Controlled Trial
Diabetes2022-05-311 citations
742-P: Phase 1 Study of Safety, Tolerability, PK, and PD of Once-Weekly Basal Insulin Fc (BIF) in Japanese Patients with T2DM
Diabetes2021-06-01